Search
Lung Cancer
S1400I (NCT02785952) Requires prior entry to S1400 Screening Study
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (LUNG MAP SUB-STUDY)
S1400K (NCT# pending) Requires prior entry to S1400 screening study.
A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG MAP SUB-STUDY)
S1400F (NCT03373760) Requires prior entry to S1400 screening study.
A Phase II Study of MED14736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
A221504 (NCT03087708)
A Randomized, Double-Blind, Placebo-Controlled Pilot of Naloxegol (an Oral, Selective Peripheral Opioid Receptor Antagonist) in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
NRG LU002 (NCT03137771)
Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.
NRG CC003 (NCT02635009) – Temporarily Closed
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Alliance C30610 (NCT00632835)
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
SWOG S1400 (NCT02154490)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
AFT09 (NCT02591615)
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer
EA5142 (NCT02595944) Must have Consented to ALCHEMIST A151216
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
